For your skin
The active in classic anti-dandruff and anti-Malassezia formulas. It is an FDA-approved OTC antidandruff active, and RCTs show it reduces flaking and the look of dandruff about as well as leading medicated washes. The reason your medicated body wash actually works.
Want the science? Keep reading ↓Mechanism of action
Zinc-chelated pyrithione that disrupts fungal membrane transport (notably Malassezia spp.) and inhibits bacterial growth; depolarises microbial cell membranes by increasing intracellular copper to toxic levels. FDA-approved OTC antidandruff active.
Why we tier this strong
6 cited papers across 2 countries. Multiple positive efficacy results plus regulatory backing. Our catalog highlights 6 cited papers as direct references, a curated sample from the broader body of published research that earns Zinc Pyrithione its Strong tier (15+ studies including multiple RCTs or a large longitudinal cohort). See our methodology for how we evaluate evidence.
Cited research
Turner GA, Matheson JR, Li GZ, Fei XQ, Zhu D, Baines FL. Enhanced efficacy and sensory properties of an anti-dandruff shampoo containing zinc pyrithione and climbazole. Int J Cosmet Sci. 2013;35(1):78-83. — clinical evaluation of the zinc pyrithione dual-active shampoo demonstrated superior anti-dandruff efficacy that was retained during a regression phase.
Reeder NL, Xu J, Youngquist RS, Schwartz JR, Rust RC, Saunders CW. The antifungal mechanism of action of zinc pyrithione. Br J Dermatol. 2011;165 Suppl 2:9-12.
Berger RS, Fu JL, Smiles KA, Turner CB, Schnell BM, Werchowski KM, Lammers KM. The effects of minoxidil, 1% pyrithione zinc and a combination of both on hair density: a randomized controlled trial. Br J Dermatol. 2003;149(2):354-362. — 1% pyrithione zinc shampoo produced a modest, sustained improvement in hair count over the 26-week treatment period.
Pierard-Franchimont C, Goffin V, Decroix J, Pierard GE. A multicenter randomized trial of ketoconazole 2% and zinc pyrithione 1% shampoos in severe dandruff and seborrheic dermatitis. Skin Pharmacol Appl Skin Physiol. 2002;15(6):434-441.
Saple DG, Ravichandran G, Desai A. Evaluation of safety and efficacy of ketoconazole 2% and zinc pyrithione 1% shampoo in patients with moderate to severe dandruff--a postmarketing study. J Indian Med Assoc. 2000;98(12):810-811. — a reduction of >90% in dandruff was seen for all scalp areas individually and collectively versus baseline.
FDA OTC Final Monograph, 21 CFR Part 358 Subpart H — Dandruff, Seborrheic Dermatitis, and Psoriasis Drug Products for OTC Human Use; pyrithione zinc listed at 0.3-2% as a Category I active.
Sources: 10 clinical journals and regulatory databases across the US, EU, Korea, Japan, and China. Every entry points to a specific document. See methodology for the full list and what each outcome label means.